Horizon Sees $30 Million

Horizon Therapeutics Inc., a Palo Alto, Calif.-based developer of “GI friendly” prescription non-steroidal anti-inflammatory drugs, has raised $30 million in Series C funding. Essex Woodlands Health Ventures led the deal, and was joined by return backers Scale Venture Partners, Sutter Hill Ventures and Pequot Ventures. Horizon has now raised $51 million in total VC funding since 2005. www.horizontherapeutics.com